The Asia Pacific Multiple Myeloma Market should witness market growth of 10.8% CAGR during the forecast period (2023-2029).
Diagnosing tumor-related abnormalities discovered through screening methods like radiography is the first step in the therapy procedures for myeloma. Radiotherapy is the first step in treating malignancies since it is a localized method that only affects the area surrounding the tumor. Radiological techniques are typically recommended as therapy choices at the asymptomatic stage of the condition. They are likewise utilized to treat pain brought on by bone deterioration in the latter stages.
Therefore, every cancer treatment must include radiotherapy. Recent developments in radiotherapy, such as its capacity to turn a circumscribed tumor into an in-situ vaccination, have increased the therapy's therapeutic window in several instances. In the treatment of multiple myeloma, radiotherapy has no viable substitute. With the disease's increasing incidence, it is therefore anticipated that the use of this method in multiple myeloma therapy will increase.
Southeast Asian countries are seeing a sharp rise in lymphoma prevalence in the region. The world's highest age-standardized rates of multiple myeloma (MM) incidence are also observed in Australia and its neighboring nations. In Australia, blood cancer affects 60,000 people. Similarly, other countries are also seeing an increase in the prevalence of hematopoietic malignancies. Leukemia, for instance, is now China's ninth-leading cancer-related cause of death. Blood cancer patients make up the third-highest percentage of patients worldwide in India. As a result, the demand for treatment methods in the region has risen due to the increased initiatives taken by different governmental and non-governmental groups in managing the illness prevalence.
The China market dominated the Asia Pacific Multiple Myeloma Market by Country in 2022, and would continue to be a dominant market till 2029; thereby, achieving a market value of $2,754.3 Million by 2029. The Japan market is estimated to grow a CAGR of 10.2% during (2023-2029). Additionally, The India market would experience a CAGR of 11.5% during (2023-2029).
Based on End-user, the market is segmented into Hospitals, Clinics, and Others. Based on Disease Type, the market is segmented into Active Multiple Myeloma and Smoldering Multiple Myeloma. Based on Drug Type, the market is segmented into Protease Inhibitors, Monoclonal Antibody, Chemotherapy and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Novartis AG, Bristol Myers Squibb Company, Amgen, Inc., AbbVie, Inc., Sanofi S.A., Johnson & Johnson, Baxter International, Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceuticals Industries Ltd., and Pfizer, Inc.
Diagnosing tumor-related abnormalities discovered through screening methods like radiography is the first step in the therapy procedures for myeloma. Radiotherapy is the first step in treating malignancies since it is a localized method that only affects the area surrounding the tumor. Radiological techniques are typically recommended as therapy choices at the asymptomatic stage of the condition. They are likewise utilized to treat pain brought on by bone deterioration in the latter stages.
Therefore, every cancer treatment must include radiotherapy. Recent developments in radiotherapy, such as its capacity to turn a circumscribed tumor into an in-situ vaccination, have increased the therapy's therapeutic window in several instances. In the treatment of multiple myeloma, radiotherapy has no viable substitute. With the disease's increasing incidence, it is therefore anticipated that the use of this method in multiple myeloma therapy will increase.
Southeast Asian countries are seeing a sharp rise in lymphoma prevalence in the region. The world's highest age-standardized rates of multiple myeloma (MM) incidence are also observed in Australia and its neighboring nations. In Australia, blood cancer affects 60,000 people. Similarly, other countries are also seeing an increase in the prevalence of hematopoietic malignancies. Leukemia, for instance, is now China's ninth-leading cancer-related cause of death. Blood cancer patients make up the third-highest percentage of patients worldwide in India. As a result, the demand for treatment methods in the region has risen due to the increased initiatives taken by different governmental and non-governmental groups in managing the illness prevalence.
The China market dominated the Asia Pacific Multiple Myeloma Market by Country in 2022, and would continue to be a dominant market till 2029; thereby, achieving a market value of $2,754.3 Million by 2029. The Japan market is estimated to grow a CAGR of 10.2% during (2023-2029). Additionally, The India market would experience a CAGR of 11.5% during (2023-2029).
Based on End-user, the market is segmented into Hospitals, Clinics, and Others. Based on Disease Type, the market is segmented into Active Multiple Myeloma and Smoldering Multiple Myeloma. Based on Drug Type, the market is segmented into Protease Inhibitors, Monoclonal Antibody, Chemotherapy and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Novartis AG, Bristol Myers Squibb Company, Amgen, Inc., AbbVie, Inc., Sanofi S.A., Johnson & Johnson, Baxter International, Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceuticals Industries Ltd., and Pfizer, Inc.
Scope of the Study
By End-user
- Hospitals
- Clinics
- Others
By Disease Type
- Active Multiple Myeloma
- Smoldering Multiple Myeloma
By Drug Type
- Protease Inhibitors
- Monoclonal Antibody
- Chemotherapy
- Others
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Novartis AG
- Bristol Myers Squibb Company
- Amgen, Inc.
- AbbVie, Inc.
- Sanofi S.A.
- Johnson & Johnson
- Baxter International, Inc.
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceuticals Industries Ltd.
- Pfizer, Inc.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Multiple Myeloma Market, by End User
1.4.2 Asia Pacific Multiple Myeloma Market, by Disease Type
1.4.3 Asia Pacific Multiple Myeloma Market, by Drug Type
1.4.4 Asia Pacific Multiple Myeloma Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 Analyst's Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Trials and Approvals
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
Chapter 4. Asia Pacific Multiple Myeloma Market by End User
4.1 Asia Pacific Hospitals Market by Country
4.2 Asia Pacific Clinics Market by Country
4.3 Asia Pacific Others Market by Country
Chapter 5. Asia Pacific Multiple Myeloma Market by Disease Type
5.1 Asia Pacific Active Multiple Myeloma Market by Country
5.2 Asia Pacific Smoldering Multiple Myeloma Market by Country
Chapter 6. Asia Pacific Multiple Myeloma Market by Drug Type
6.1 Asia Pacific Protease Inhibitors Market by Country
6.2 Asia Pacific Monoclonal Antibody Market by Country
6.3 Asia Pacific Chemotherapy Market by Country
6.4 Asia Pacific Others Market by Country
Chapter 7. Asia Pacific Multiple Myeloma Market by Country
7.1 China Multiple Myeloma Market
7.1.1 China Multiple Myeloma Market by End User
7.1.2 China Multiple Myeloma Market by Disease Type
7.1.3 China Multiple Myeloma Market by Drug Type
7.2 Japan Multiple Myeloma Market
7.2.1 Japan Multiple Myeloma Market by End User
7.2.2 Japan Multiple Myeloma Market by Disease Type
7.2.3 Japan Multiple Myeloma Market by Drug Type
7.3 India Multiple Myeloma Market
7.3.1 India Multiple Myeloma Market by End User
7.3.2 India Multiple Myeloma Market by Disease Type
7.3.3 India Multiple Myeloma Market by Drug Type
7.4 South Korea Multiple Myeloma Market
7.4.1 South Korea Multiple Myeloma Market by End User
7.4.2 South Korea Multiple Myeloma Market by Disease Type
7.4.3 South Korea Multiple Myeloma Market by Drug Type
7.5 Singapore Multiple Myeloma Market
7.5.1 Singapore Multiple Myeloma Market by End User
7.5.2 Singapore Multiple Myeloma Market by Disease Type
7.5.3 Singapore Multiple Myeloma Market by Drug Type
7.6 Malaysia Multiple Myeloma Market
7.6.1 Malaysia Multiple Myeloma Market by End User
7.6.2 Malaysia Multiple Myeloma Market by Disease Type
7.6.3 Malaysia Multiple Myeloma Market by Drug Type
7.7 Rest of Asia Pacific Multiple Myeloma Market
7.7.1 Rest of Asia Pacific Multiple Myeloma Market by End User
7.7.2 Rest of Asia Pacific Multiple Myeloma Market by Disease Type
7.7.3 Rest of Asia Pacific Multiple Myeloma Market by Drug Type
Chapter 8. Company Profiles
8.1 Johnson & Johnson
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental &Regional Analysis
8.1.4 Research & Development Expenses
8.1.5 Recent strategies and developments:
8.1.5.1 Trials and Approvals:
8.1.5.2 Acquisition and Mergers:
8.1.6 SWOT Analysis
8.2 Novartis AG
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Segmental and Regional Analysis
8.2.4 Research & Development Expense
8.2.5 Recent strategies and developments:
8.2.5.1 Partnerships, Collaborations, and Agreements:
8.2.5.2 Product Launches and Product Expansions:
8.3 Sanofi S.A.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Segmental and Regional Analysis
8.3.4 Research & Development Expense
8.3.5 Recent strategies and developments:
8.3.5.1 Partnerships, Collaborations, and Agreements:
8.3.5.2 Trials and Approvals:
8.4 Amgen, Inc.
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Regional Analysis
8.4.4 Research & Development Expenses
8.4.5 Recent strategies and developments:
8.4.5.1 Trials and Approvals:
8.4.5.2 Acquisition and Mergers:
8.5 AbbVie, Inc.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Regional Analysis
8.5.4 Research & Development Expense
8.5.5 Recent strategies and developments:
8.5.5.1 Partnerships, Collaborations, and Agreements:
8.6 Baxter International, Inc.
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expense
8.6.5 Recent strategies and developments:
8.6.5.1 Acquisition and Mergers:
8.7 Teva Pharmaceutical Industries Ltd.
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Regional Analysis
8.7.4 Research & Development Expenses
8.7.5 Recent strategies and developments:
8.7.5.1 Product Launches and Product Expansions:
8.8 Pfizer, Inc.
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Regional & Segmental Analysis
8.8.4 Research & Development Expense
8.8.5 Recent strategies and developments:
8.8.5.1 Acquisition and Mergers:
8.9 Bristol Myers Squibb Company
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Regional Analysis
8.9.4 Research & Development Expenses
8.9.5 Recent strategies and developments:
8.9.5.1 Trials and Approvals:
8.9.5.2 Acquisition and Mergers:
8.10. Takeda Pharmaceutical Company Limited
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Regional Analysis
8.10.4 Research & Development Expense
Companies Mentioned
- Novartis AG
- Bristol Myers Squibb Company
- Amgen, Inc.
- AbbVie, Inc.
- Sanofi S.A.
- Johnson & Johnson
- Baxter International, Inc.
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceuticals Industries Ltd.
- Pfizer, Inc.
Methodology
LOADING...
